Below are articles from various sources about members of MCB and their research.
Associate Adjunct Professor of Genetics, Genomics and Development Fyodor Urnov's career is featured in the April edition of ASBMB Today. His current endeavors target the inherited blood diseases beta-thalassemia and sickle-cell, offering alternatives to current treatments through gene editing, while still inspiring Berkeley undergraduates.
"MCB cancer immunologists are teaming up with colleagues working on infectious disease to create a new Immunotherapeutics and Vaccine Research Initiative, fueled by $7.5 million in funding from Aduro Biotech Inc., a Berkeley company that develops immunotherapies for cancer and other diseases."
Professor Emeritus of Berkeley's Biochemistry Department (now a part of Molecular and Cell biology), Roger David Cole, passed away at age 91 in Santa Barbara on March 13, 2016. Cole worked at Berkeley from 1958 until 1992, when he retired as Assistant Dean in the College of Letters and Science.
MCB Professor of Biochemistry, Biophysics and Structural Biology Jennifer Doudna has been honored with the 2016 Canada Gairdner International Award. There were four additional recipients, including Doudna's original collaborator, Emmanuelle Charpentier, and three others -- Feng Zhang, Rodolphe Barrangou, and Philippe Horvath.
Associate Professor of Plant and Microbial Biology (and affiliate of MCB's Division of Cell and Developmental Biology) Arash Komeili, and his collaborators, which include MCB Professors Michelle Chang and James Hurley, have discovered how magnetic compasses form in bacteria, which allow them to navigate their environment.
Assistant Professor of Cell and Developmental Biology Polina Lishko, and her postdoc Melissa Miller have "discovered the switch that triggers the power kick sperm use to penetrate and fertilize a human egg." Their findings are published in the “Fast Release” issue of the journal Science.
The Cancer Research Lab (CRL) and CEND (The Center for Emerging and Neglected Diseases) are joining forces to help launch a new campus initiative called the Immunotherapeutics and Vaccine Research Initiative or IVRI. The official launch is on March 24-25, 2016 to coincide with a Symposium on Immunotherapy on the UC Berkeley campus.